Form 4: Director Robert DeSutter Receives Sanara MedTech Grant
Director Equity Grant
Director Robert A. DeSutter was granted 5,539 shares of restricted common stock by Sanara MedTech Inc.
Summary
- Director Robert A. DeSutter acquired 5,539 shares of Sanara MedTech Inc. (SMTI) common stock.
- The shares were granted as restricted stock under the 2024 Omnibus Long-Term Incentive Plan.
- The grant has a zero-dollar cost basis to the director.
- Following this transaction, the director's total beneficial ownership is 28,740 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention of key leadership through a one-year vesting schedule.
Negatives
- Minor dilution of existing shareholders due to the issuance of new restricted stock.
Risks
- Vesting is contingent upon the director continuing to provide services to the issuer through the vesting date.
Future Outlook
The restricted stock is scheduled to vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, subject to continued service.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the medical technology sector to ensure long-term alignment between board members and shareholders.
Comparison to Industry Standards
- The use of an Omnibus Long-Term Incentive Plan is consistent with standard practices for mid-cap medical device companies.
- Vesting periods of one year for director equity are common in the industry to balance retention with performance incentives.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of restricted stock under the 2024 Omnibus Long-Term Incentive Plan. | 06/04/2026 | Increases director equity stake, aligning interests with shareholders. |
Stakeholder Impact
- Shareholders: Minor dilution impact.
- Director: Increased financial stake in company performance.
Next Steps
- Vesting of the 5,539 shares on or before June 4, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/04/2026 | Date of the restricted stock grant transaction. |
| 06/05/2026 | Date the Form 4 was signed and filed. |
| 06/04/2027 | Vesting date for the restricted stock grant. |
Keywords
Sanara MedTech, SMTI, Form 4, Insider Trading, Equity Grant, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.